ConductScience.org, home
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
API referenceFor AI assistants

Trial · NCT02839330

Results by group188

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 188

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Primary Immunogenicity Endpoint: Geometric Mean Titer (GMT) at Day 43 by LotGroup A: aH5N1c Lot #1Day 116.195% Confidence Interval 15.1 to 17.2geometric mean titer
Primary Immunogenicity Endpoint: Geometric Mean Titer (GMT) at Day 43 by LotGroup B: aH5N1c Lot #2Day 117.095% Confidence Interval 15.9 to 18.2geometric mean titer
Primary Immunogenicity Endpoint: Geometric Mean Titer (GMT) at Day 43 by LotGroup C: aH5N1c Lot #3Day 117.095% Confidence Interval 15.9 to 18.2geometric mean titer
Primary Immunogenicity Endpoint: Geometric Mean Titer (GMT) at Day 43 by LotGroup A: aH5N1c Lot #1Day 43128.695% Confidence Interval 118.9 to 139.1geometric mean titer
Primary Immunogenicity Endpoint: Geometric Mean Titer (GMT) at Day 43 by LotGroup B: aH5N1c Lot #2Day 43127.495% Confidence Interval 117.6 to 138.0geometric mean titer
Primary Immunogenicity Endpoint: Geometric Mean Titer (GMT) at Day 43 by LotGroup C: aH5N1c Lot #3Day 43132.295% Confidence Interval 122.1 to 143.1geometric mean titer
Primary Immunogenicity Endpoint: Percentage of Subjects With Haemagglutination Inhibition (HI) Titer ≥ 1:40 at Day 43 by Age CohortaH5N1cDay 1, 18 to <65 years13.095% Confidence Interval 10.7 to 15.6percentage of subjects
Primary Immunogenicity Endpoint: Percentage of Subjects With Haemagglutination Inhibition (HI) Titer ≥ 1:40 at Day 43 by Age CohortPlaceboDay 1, 18 to <65 years15.095% Confidence Interval 11.5 to 19.4percentage of subjects
Primary Immunogenicity Endpoint: Percentage of Subjects With Haemagglutination Inhibition (HI) Titer ≥ 1:40 at Day 43 by Age CohortaH5N1cDay 1, ≥65 Years27.895% Confidence Interval 24.9 to 30.9percentage of subjects
Primary Immunogenicity Endpoint: Percentage of Subjects With Haemagglutination Inhibition (HI) Titer ≥ 1:40 at Day 43 by Age CohortPlaceboDay 1, ≥65 Years24.595% Confidence Interval 20.1 to 29.6percentage of subjects
Primary Immunogenicity Endpoint: Percentage of Subjects With Haemagglutination Inhibition (HI) Titer ≥ 1:40 at Day 43 by Age CohortaH5N1cDay 43, 18 to <65 years95.095% Confidence Interval 93.4 to 96.2percentage of subjects
Primary Immunogenicity Endpoint: Percentage of Subjects With Haemagglutination Inhibition (HI) Titer ≥ 1:40 at Day 43 by Age CohortPlaceboDay 43, 18 to <65 years8.595% Confidence Interval 5.9 to 12.1percentage of subjects
Primary Immunogenicity Endpoint: Percentage of Subjects With Haemagglutination Inhibition (HI) Titer ≥ 1:40 at Day 43 by Age CohortaH5N1cDay 43, ≥65 Years85.795% Confidence Interval 83.3 to 87.9percentage of subjects
Primary Immunogenicity Endpoint: Percentage of Subjects With Haemagglutination Inhibition (HI) Titer ≥ 1:40 at Day 43 by Age CohortPlaceboDay 43, ≥65 Years20.895% Confidence Interval 16.6 to 25.8percentage of subjects
Percentage of Subjects With Solicited Local, Solicited Systemic, and Other Adverse Events (AEs) as Measured for 7 Days (Inclusive) Following Each VaccinationaH5N1cAny Solicited AE, After Any Vac (D1-D7 excl 30m)59.7percentage of subjects
Percentage of Subjects With Solicited Local, Solicited Systemic, and Other Adverse Events (AEs) as Measured for 7 Days (Inclusive) Following Each VaccinationPlaceboAny Solicited AE, After Any Vac (D1-D7 excl 30m)38.0percentage of subjects
Percentage of Subjects With Solicited Local, Solicited Systemic, and Other Adverse Events (AEs) as Measured for 7 Days (Inclusive) Following Each VaccinationaH5N1cSolicited Loc AE, After Any Vac (D1-D7 excl 30m)50.2percentage of subjects
Percentage of Subjects With Solicited Local, Solicited Systemic, and Other Adverse Events (AEs) as Measured for 7 Days (Inclusive) Following Each VaccinationPlaceboSolicited Loc AE, After Any Vac (D1-D7 excl 30m)14.7percentage of subjects
Percentage of Subjects With Solicited Local, Solicited Systemic, and Other Adverse Events (AEs) as Measured for 7 Days (Inclusive) Following Each VaccinationaH5N1cSolicited Sys AE, After Any Vac (D1-D7 excl 30m)38.2percentage of subjects
Percentage of Subjects With Solicited Local, Solicited Systemic, and Other Adverse Events (AEs) as Measured for 7 Days (Inclusive) Following Each VaccinationPlaceboSolicited Sys AE, After Any Vac (D1-D7 excl 30m)32.8percentage of subjects

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02839330/results

API referenceFor AI assistants